ANI PHARMACEUTICALS INC - 8-K Filing
ANI Pharmaceuticals reported first-quarter 2026 revenue of $237.5 million, up 20.5% year-over-year, with Cortrophin Gel net revenues at $75.1 million (up 42.1%). GAAP net income was $29.5 million ($1.28 per diluted share), and adjusted non-GAAP EBITDA rose to $63.0 million (+24.1% YoY). The company raised full-year revenue guidance to $1,080–$1,140 million and adjusted non-GAAP EBITDA to $285–$300 million. (Items: 2.02 of this Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act)
Tickers: $ANIP